Table 3 Multivariate analysis graft versus host disease, non relapse mortality and cumulative incidence of relapse.

From: Impact of anti-T-lymphocyte globulin dosing on graft versus host disease in matched sibling peripheral blood stem cell transplantation

 

NRM

HR [95% CI] p value

Patient age per 1 yr increase

1.048 [0.976, 1.120] 0.20

ATLG-30 vs ATLG-15

0.398 [0.122, 1.300] 0.13

DRSS High-risk vs Low-risk

0.631 [0.176, 2.250] 0.48

 

CIR

 

HR [95% CI] p value

Patient Age (per 1 yr increase)

1.021 [0.994, 1.050] 0.12

ATLG-30 vs ATLG-15

1.314 [0.661, 2.610] 0.44

Donor Sex: Female vs Male

0.854 [0.450, 1.620] 0.63

DRSS: Intermediate 1 vs Standard

0.947 [0.287, 3.120] 0.93

DRSS: Intermediate 2 vs Standard

1.133 [0.372, 3.450] 0.83

DRSS: High vs Standard

0.891 [0.193, 4.120] 0.88

DRSS: Very High vs Standard

3.370 [1.102, 10.310] 0.03

TBI: TBI vs no TBI

2.507 [1.040, 6.040] 0.04

 

aGVHD24

aGVHD34

 

HR [95% CI] p value

HR [95% CI] p value

Patient age per 1 yr increase

1.015 [0.987, 1.04] 0.300

1.023 [0.975, 1.07] 0.3600

Year of Transplant per 1 yr increase

1.018 [0.837, 1.24] 0.860

0.987 [0.698, 1.40] 0.9400

ATLG-30 vs ATLG-15

0.708 [0.340, 1.47] 0.360

0.623 [0.216, 1.79] 0.3800

Patient CMV serology pos vs neg

2.403 [1.303, 4.43] 0.005

1.608 [0.652, 3.97] 0.3000

Donor sex Female vs Male

1.747 [0.959, 3.18] 0.068

1.388 [0.562, 3.43] 0.4800

RIC vs MAC

1.603 [0.859, 2.99] 0.140

5.893 [1.714, 20.26] 0.0049

 

cGVHD all

cGVHD moderate/Severe

 

HR [95% CI] p value

HR [95% CI] p value

Patient age per 1 yr increase

0.993 [0.976, 1.01] 0.48

1.004 [0.977, 1.031] 0.780

Year of Transplant per 1 yr increase

1.002 [0.880, 1.14] 0.98

0.922 [0.792, 1.073] 0.290

ATLG-30 vs ATLG-15

0.810 [0.463, 1.41] 0.46

0.450 [0.214, 0.946] 0.035

RIC vs MAC

0.814 [0.474, 1.40] 0.46

1.185 [0.656, 2.141] 0.570

No TBI vs TBI

0.760 [0.334, 1.73] 0.51

 

CR vs not CR

1.106 [0.649, 1.89] 0.71

 

CD34 Dose

0.935 [0.851, 1.03] 0.15

 
  1. CIR Cumulative Incidence of Relapse, NRM Non-Relapse Mortality, HR Hazard Ratio, CI Confidence Interval, CR Complete Remission, TBI Total Body Irradiation, aGVHD24 Acute Graft-versus-Host Disease (Grades 2–4), aGVHD34 Acute Graft-versus-Host Disease (Grades 3–4), cGVHD Chronic Graft-versus-Host Disease, ATLG Anti-T-Lymphocyte Globulin, RIC Reduced-Intensity Conditioning, MAC Myeloablative Conditioning, CMV Cytomegalovirus, CD34 Dose Infused CD34⁺ Cell Dose (×10⁶ cells/kg), DRSS Disease Risk Stratification System (Standard, Intermediate 1/2, High, Very High; grouped into Low-risk vs High-risk for NRM analysis).
  2. Red: p < 0.05, Bold: p < 0.1.
Back to article page